Macro and microvasculature in hypertension: therapeutic aspects

Size: px
Start display at page:

Download "Macro and microvasculature in hypertension: therapeutic aspects"

Transcription

1 (2008) 22, & 2008 Macmillan Publishers Limited All rights reserved /08 $ REVIEW Macro and microvasculature in hypertension: therapeutic aspects ME Safar 1, D Rizzoni 2, J Blacher 1, ML Muiesan 2 and E Agabiti-Rosei 2 1 Faculty of Medicine, Diagnosis and Therapeutic Center, AP-HP, Hôtel-Dieu Hospital, Paris Descartes University, Paris, France; 2 Clinica Medica, Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy Macrovasculature, microvasculature and the heart determine the structure and function of the circulatory system. Due to the viscoelastic properties of large arteries, the pulsatile pressure and flow that result from intermittent ventricular ejection is smoothed out, so that microvasculature mediates the delivery of nutrients and oxygen to tissues steadily. The disruption of this function, which occurs when microvascular structure develops in response to hypertension, leads to end-organ damage. Microvascular structure is not only the site of vascular resistance, but also the origin of most of the wave reflections generating increased central systolic blood pressure (SBP) in the elderly. Nowadays many data of the literature suggest that hypertension-related damage to the micro and macrovascular system may be manageable through pharmacological agents. Among them, b-blocking agents and diuretics poorly modify microvascular structure, whereas angiotensin and calcium entry blockade has an opposite effect, thereby reducing central wave reflections and, finally, causing a selective SBP reduction. (2008) 22, ; doi: /jhh ; published online 29 May 2008 Keywords: anti-hypertensive therapy; macrovasculature; microvasculature Introduction The heart and the vasculature determine the haemodynamics of the circulatory system. As the blood progresses through the arterial tree towards the periphery, the pulsatile pressure and its consequences that result from the intermittent ventricular ejection of the blood in the macrocirculation are smoothed out, thereby allowing a steady oxygen flow to the tissues (microcirculation). The blood pressure (BP) curve has two components: the constant mean arterial pressure (MAP), a measure of cardiac output and vascular resistance, and the pulse pressure (PP), a measure of the pressure fluctuations, the elasticity of large arteries, and the timing, velocity (pulse wave velocity, PWV), and the intensity of the arterial wave reflections. PP and mostly systolic blood pressure (SBP) vary across the arterial tree and increase peripherally with the decline in artery diameter, the increase in arterial stiffness and the transit of wave reflections. 1,2 Anti-hypertensive therapy largely prevents the cerebral and renal complications of hypertension as Correspondence: Professor ME Safar, Centre de Diagnostic et de Thérapeutique, Hôtel-Dieu, 1, Place du Parvis Notre-Dame, Paris Cedex 04, France. Michel.Safar.Hotel-Dieu.Paris@wanadoo.fr Received 28 January 2008; revised 17 March 2008; accepted 8 April 2008; published online 29 May 2008 well as the development of congestive heart failure. The prevention of coronary ischaemic disease is more difficult to obtain. This aspect is important to consider because, during chronic treatment, it is difficult to normalize SBP (o140 mm Hg) and much easier to control adequately diastolic blood pressure (DBP) (o90 mm Hg). 3 This aspect is important to consider because, in the absence of treatment, two kinds of hypertension are usually defined: systolic (X140 mm Hg) diastolic (X90 mm Hg) hypertension in the middle age; systolic (X140 mm Hg) hypertension in older subjects, particularly in subjects with low (p90 mm Hg) DBP. International guidelines consider that the normalisation of SBP is nowadays a priority of anti-hypertensive drug therapy. This situation requires to fully investigate the principal pathophysiological mechanisms explaining increased SBP within large and small arteries. Our working hypothesis, in this editorial review, involves the following three propositions: (1) disturbed stiffness and wave reflections, which affect mainly the hypertensive large arteries (macrocirculation), are the two major factors determining SBP, mainly in subjects with systolic hypertension in the elderly, in the absence of heart failure, (2) wave reflections develop particularly at the site of arteriolar bifurcations, which are the major site of the structural arteriolar changes observed in the hypertensive microcirculation, and (3) it is expected that the reversibility of arteriolar structural changes

2 may be a major pre-requisite to obtain a selective reduction of SBP in subjects treated for hypertension. This editorial involves in hypertensive subjects two different descriptions: structure and function of the microcirculation; macrocirculation and control of SBP and PP under treatment. Note that the classical and arbitrary limit between macro and microvessels corresponds to an internal arterial diameter of 400 mm. Myogenic tone, which operates at the intersection of macro and microvasculature and is at the origin of organ autoregulation, will be considered as out of the scope of this review. Structure and function of the microvasculature in hypertension Vascular resistance and MAP are the main haemodynamic components that are determined by the microvasculature. The increase in MAP observed in subjects with hypertension of the middle age is known to be largely due to an increase in vascular resistance, causing a parallel increase in both SBP and DBP. As a consequence of the Poiseuille s law, increase in vascular resistance is considered to be the principal haemodynamic hallmark of hypertension. 4 Studies performed in animals and humans have determined that in response to the chronic increase in resistance, cells of the arteriolar vessels adapt structurally and functionally. Not only is the extracellular material re-arranged, but also the smooth muscle cells, which get activated, may migrate and proliferate. Together, these two events alter the thickness of the vascular wall. The overall result is a reduction in the calibre of small arteries and arterioles with an increase in the wall to lumen ratio. 4 Basic concepts on the hypertensive microvasculature Resistance vessel structure is a difficult quantity to measure. In vitro studies of isolated resistance vessels have the advantage of precise measurements of vascular dimensions without fixation artifacts. If measurements are confined to an evaluation of the ratio of wall thickness to lumen diameter ( wall: lumen ratio ), or, with measurements of tunica media thickness ( media:lumen ratio ), by general agreement this parameter is increased in hypertension, at least in the more proximal resistance vessels (internal diameter between 400 and 100 mm). In fact, the ratio between media thickness and internal diameter is considered, at present, the most reliable indicator of microvascular structure, as it is independent from vessels dimensions. In the past two decades, the presence of structural alterations in subcutaneous and omental small resistance arteries dissected from biopsies performed in essential hypertensive patients has been confirmed with a direct investigation using the micromyographic method. 4 In fact, patients with essential hypertension show the presence of an increased tunica media to lumen ratio, without any relevant increase of the total amount of wall tissue, as indicated by a media cross-sectional area similar to that observed in normotensive controls. The major part of the structural changes observed in essential systolic diastolic hypertension is the consequence of eutrophic remodelling (re-arrangement of the same amount of wall material around a narrowed lumen), without net cell growth. On the contrary, in patients with some forms of secondary hypertension (renovascular hypertension and primary aldosteronism), or diabetes mellitus a more evident contribution of cell growth, leading to the development of hypertrophic remodelling (vascular smooth muscle cell hypertrophy or hyperplasia), may be usually observed. It is now therefore widely accepted that structural abnormalities of microvessels are common alterations associated with chronic hypertension. 4 It has been proposed that this section of the arterial tree may be important in the development of hypertension, and may also contribute to its complications. However, interrelationships between BP and vascular structure are complex. At present there is no clear evidence about the possible role of vascular structural changes in initiating hypertension. It has been proposed that structural alterations in the resistance vasculature may act as a vascular amplifier, able to enhance the effects of any hypertensive stimulus, 5, but there is also some disagreement about this amplifier hypothesis. 6 A complex interplay between vascular structure and function as well as neurohumoral factors may be postulated. 7 Also the time course of the development of changes in morphological and mechanical aspects of resistance arteries in hypertension may be described but remains partially unclear. 8 Microvasculature and hypertensive CV risk A significant correlation between media to lumen ratio of subcutaneous small resistance arteries and SBP, DBP and MAP has been observed in a relatively large population of normotensive subjects and hypertensive patients. 8 Similar results were obtained in a small number of patients with and without left ventricular hypertrophy. 9 Recently, we have investigated possible relationships between subcutaneous small resistance artery structure, and BP values in a population of more than 200 normotensive subjects and hypertensive patients. Among the most important predictors of small artery structure there were clinic SBP, DBP and mean BP, 24-h SBP and DBP, and the ratio between the PP and stroke volume, taken as an indirect index of large artery distensibility (Figure 1; D Rizzoni and E Agabiti-Rosei, unpublished data). 591

3 592 M/L Spearman correlation coefficient: 0.23, p=0.008 n= PP/SV Figure 1 Correlation between pulse pressure/stroke volume (PP/SV) ratio and media to lumen ratio of subcutaneous small resistance arteries (M/L) (D Rizzoni, unpublished data). and so on, did not enter the model. The relevant prognostic role of small resistance artery structure has been recently confirmed in a medium-risk hypertensive patients cohort. 12,13 We have also re-evaluated our prognostic data taking into account also the characteristics of the vascular remodelling. For the same values of internal diameter, those subjects who suffered CV events had a greater media-cross-sectional area, in comparison with those without CV events 14 (Figure 2). Therefore, it seems that, for the same size of the vessels explored, a more consistent cell growth (hypertrophic remodelling) means an even worse prognosis. It has also been recently proposed that alterations in the microcirculation may be involved in the abrupt rise of BP during the morning hours, which is, in turn, associated with increased incidence of CV events. 15 Figure 2 Possible role of hypertrophic remodelling in the occurrence of cardiovascular events in high-risk patients. 14 For any value of internal diameter, subjects and patients with cardiovascular events have a greater media cross-sectional area (MCSA) compared to those without cardiovascular events. Regardless of the presence or absence of a causal relationship between small artery structure and hypertension, an important consequence of the presence of structural alterations in small resistance arteries and arterioles may be an impairment of organ vasodilator reserve. 10 The presence of structural alterations in the microcirculation may represent an important link between hypertension and ischaemic heart disease, cerebral damage or renal failure. In fact, a relationship between structural alterations in the subcutaneous small resistance arteries and the occurrence of cardiovascular (CV) events, has been previously demonstrated in a relatively large population during a follow up of 5.6 years. 11 In this study the media to lumen ratio of subcutaneous small resistance arteries represented, together with clinic PP, the most potent predictor of CV events in a relatively high-risk population. 11 Brachial PP (macrovasculature) and media to lumen ratio of subcutaneous small arteries (microvasculature) were found to be significantly associated with the occurrence of CV events (Cox proportional hazard model). Other CV risk factors, including age, gender, cholesterol levels, left ventricular mass Microvasculature and chronic anti-hypertensive drug therapy According to the previously mentioned observations, the possible regression of vascular alterations in small resistance arteries of subjects with systolic diastolic hypertension is an appealing goal of antihypertensive treatment. Some intervention studies have demonstrated an improvement or even an almost complete normalisation of the structure of subcutaneous small resistance arteries with angiotensin converting enzyme (ACE) inhibitors (cilazapril, perindopril (Per) and lisinopril), 9,16,17 calcium channel blockers (nifedipine, amlodipine and irsradipine) and 16,17 angiotensin II receptor blockers (losartan, irbesartan, candesartan and valsartan) On the contrary, the b-blocker atenolol and the diuretic hydrochlorothiazide had lesser effects on resistance vessels and on brachial PP, despite a BP reduction similar to that observed with ACE inhibitors. 16,17 Such findings are widely observed in systolic diastolic hypertension but have been poorly investigated in subjects with systolic hypertension, mainly when DBP is low (o90 mm Hg). In one of these studies, performed in hypertensive patients with non-insulin-dependent diabetes mellitus, 18 brachial PP was significantly higher in patients than in normotensive subjects before random assignment and it was significantly reduced only by the angiotensin AT1 receptor antagonist valsartan, whereas no change was observed with atenolol. Brachial PP was correlated with age, duration of diabetes and hypertension. According to the authors of the study, 18 differences in haemodynamic actions could contribute to the heterogeneous impact of these drugs on small artery structure. Vasoconstriction may represent one of the mechanisms leading to eutrophic remodelling as the vasoconstricted state becomes embedded in the newly secreted extracellular matrix. Therefore, vasodilation rather than specific actions of the

4 anti-hypertensive agents used could be involved in the correction of eutrophic remodelling. 19 Valsartan acts as a vasodilator through inhibition of the vascular effects of angiotensin II, whereas the b- blocking agent atenolol may induce vasoconstriction and may reduce blood flow. In addition, under atenolol the downstream increase in impedance at the level of the remodelled arteries may cause early reflected waves and an upstream increase in transmural pressure at the level of central elastic arteries that may lead to increased SBP and arterial stiffness. Although during the study BP was equally well controlled in both the groups, at the end of the study brachial SBP was 5 mm Hg (P ¼ NS, not significant) higher in the atenolol than in the valsartan group. As previously mentioned, valsartan but not atenolol reduced brachial PP, a marker of arterial stiffness in the presence of preserved ejection fraction. 1,2 Stiffness of small arteries (evaluated by the stress strain relationships) was, in fact, enhanced in patients treated with atenolol, and a similar change may have also occurred in large arteries. 18 This may explain differences in brachial SBP and also different effects of the drugs on small artery remodelling at the end of the study. It should however be mentioned that no correlation was observed between changes in brachial PP and changes in vascular structure when all the available studies are considered together (D Rizzoni and E Agsbiti-Rosei, unpublished data). There is, in any case, a dissociation between control of brachial BP and effects on vascular structure, as there was no difference in brachial BP-lowering effect between effective (ACE inhibitors, angiotensin receptor blockers and calcium antagonists) or ineffective (b-blockers and diuretics) therapeutic strategies, although different drugs may possess different vasodilator properties. 19 None of these studies has, however, analysed in detail whether a relationship exists between decrease of media to lumen ratio of small arteries and BP components, that is, brachial and also central BP. This lack of data is particularly true regarding diuretic compounds (mainly thiazides) 2,8,16 when given in long-term treatment. Recently, a significant reduction in small resistance artery stiffness was observed in essential hypertensive patients treated with a selective mineralocorticoid receptors blocker eplerenone, but not in those treated with atenolol. 20 This beneficial effect was associated with a normalisation of the media collagen/elastin ratio, thus suggesting that antihypertensive treatment may normalize mechanical alterations also in human small resistance arteries. Control of SBP and PP: role of macrovasculature and wave reflections Ventricular ejection in humans is associated with an acute shock of stroke volume against the aortic wall. Thereafter, the BP curve may be considered as a wave, which travels along the arterial tree at a given speed, the PWV. 1,2 The PWV level is an indirect measurement of aortic stiffness: the higher the PWV, the stiffer the arterial wall and the higher the SBP at any given value of stroke volume. Thereafter, two major events characterize the BP curve. First, at each discontinuity of the arterial wall, the incident pressure wave may be reflected. Second, the summation of the incident (coming from the heart) and the reflected (returning towards the heart) waves determine the shape of the BP curve at each site of the arterial tree. With age, this shape is more and more influenced by the timing and amplitude of the reflected wave, which returns towards the heart at the same PWV as the incident wave. 1,2 Thus, PWV is a major marker of biological aging. Pressure waves are reflected at every discontinuity of the arterial wall, but reflections predominate at the sites of arteriolar bifurcations, where the geometry and stiffness of vessel wall material determine the reflection angle and, therefore, the value of its coefficient Herein, the major factors to consider are not only the distensibility and the diameter of each arteriolar branch of the bifurcation, but also their exact location. With age, the reflection sites are closer to vital organs, such as the heart, brain and kidney, and even wave reflections may contribute particularly to organ damage. 1,2,24 Wave reflections may occur at any vascular site where vasomotor tone and pulsatility are still present. They disappear almost completely at pre-capillary and capillary levels (diameter: o150 mm), that is, when blood perfusion becomes almost completely steady. Macrovasculature and CV risk From a pathophysiological viewpoint, the reflected pressure wave is markedly influenced by vascular aging. 1,2 When subjects are young and have quite elastic conduit arteries (low PWV), the reflected wave returns slowly towards the heart, that is, during the diastolic period. Its principal consequence is to boost coronary perfusion during this period without changing the cardiac afterload. On the other hand, when the subjects are old and have stiff arteries, the reflected wave returns very rapidly towards the heart (high PWV), that is, during systole. 1,2 In this setting, coronary perfusion, which normally occurs only during diastole, is consistently reduced and favours coronary ischaemia. Furthermore, in the central arteries, the reflected pressure wave becomes superimposed on the forward wave during systole and causes an additive increase of SBP, called the augmentation pressure (mm Hg) or augmentation index (%PP). Consistent with this pathophysiological understanding of hypertension and end-organ damage, PP, aortic stiffness and pressure wave reflections have been shown to produce mainly systolic hypertension and to be 593

5 594 Table 1 Forward (P t ) and backward (P b ) wave reflections and reflection coefficients (P b /P t ) in normotensive and hypertensive patients under baseline conditions and in hypertensive patients after captopril administration Parameter Normotensive (baseline) Hypertensive (n ¼ 12) Baseline P* Captopril P* Pressure wave components (mm Hg) Forward (P t ) 31.9± ± ±4.9z Backward (P b ) 13.7± ± ±5.3w P b /P t 0.43± ± ±0.09w 0.01 f 0 (Hz) 3.1± ± ±1.2 NS Abbreviation: NS, not significant. f 0 indicates first zero crossing of impedance phase angle. *Vs normotensive baseline. w Po0.005, z Po0.05 vs hypertensive baseline by paired t-test. independent predictors of CV risk (see reviews in2). For instance, in the Framingham Heart Study and in the Syst-Eur Study, brachial PP was shown to be superior to SBP as a predictor of coronary heart disease in subjects more than 60 years. 2 This relationship between brachial PP and CV risk is maintained in high-risk groups such as individuals with left ventricular dysfunction, end-stage renal disease, or diabetes mellitus. 2 Macrovasculature, wave reflections and anti-hypertensive therapy The role of arterial stiffness and wave reflections in the mechanisms of SBP reduction in subjects under anti-hypertensive drug therapy was primarily observed from the monitoring of brachial and carotid SBP and PP in the Reason Study 25 and further firmly confirmed. 26,27 This controlled trial compared the b-blocking agent atenolol to low doses of the combination of the diuretic indapamide (Ind) with the ACEI Per. After 1 year, for the same DBP reduction, Per/Ind lowered brachial (peripheral artery) and carotid (central artery) SBP and PP more than atenolol. 25 The reductions of carotid SBP and PP were significantly more pronounced than those of brachial SBP and PP, but this effect was seen exclusively with Per/Ind. Although carotid and aortic PP did not change significantly under atenolol, Per/Ind achieved a significant central PP reduction together with a selective reduction of cardiac hypertrophy. 28 The two drug regimens caused the same aortic PWV reduction as a result of the comparable decreases of MAP and DBP. The major difference between the two drug regimens was that Per/Ind lowered the carotid augmentation index, a classic marker of carotid wave reflections, 1,2 but atenolol did not. Nebivolol might have an intermediate effect. 29 The difference between Per/Ind and atenolol could be due exclusively to the atenolol-induced heart rate reduction, thereby causing the maintenance of disturbed wave reflections However, this result was observed only within the first 6 months of treatment. 25 After this period, the Reason Study showed that the mechanism of SBP reduction under Per/Ind was highly modified. After 1 year of drug treatment, structural arteriolar changes are known to be constantly and significantly reversed under ACEI by Per but never under atenolol or diuretics given alone. 1,2,16,17 We suggest that the reversion of structural arteriolar changes is responsible per se for the selective reduction of SBP and PP for two reasons. First, the selective reduction of SBP and PP becomes significant only after 1 year of treatment. 1,2,16 Second, ACEI, but not atenolol, is known to reduce reflection coefficients (Table 1) In conclusion, there is hardly any doubt that CV events are the consequences of vascular damage at both the macro and microvascular level. Possible interrelationships between alterations in the macro and microvasculature and mechanisms possibly involved represent an extremely interesting topic, which deserve further and thorough investigation, also considering its relevant clinical impact, especially in terms of possible prevention or regression of the concerned alterations. An important possibility in the future is that regression of structural vascular changes should become a necessity, particularly at the site of microvasculature, to prevent the occurrence of CV events. There is a strong need of a study aimed at evaluating possible relationships between indicators of small resistance artery structure and of large artery distensibility (for example PWV, augmentation index and so on) both in basal condition and under anti-hypertensive drug treatment. Acknowledgements This review was prepared with the help of INSERM (Institut de la Santé et de la Recherche Médicale) and GPH-CV (Groupe de Pharmacologie et d Hémodynamique Cardiovasculaire), Paris. We thank Dr Anne Safar for helpful and stimulating discussions. Disclosures None.

6 References 1 Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: Arterial stiffness in hypertension. In: Safar ME, O Rourke HF (eds). Handbook of Hypertension, ol. 23 Elsevier Publishing: Edinburgh, pp 3 62, , Black HR. The paradigm has shifted to systolic blood pressure. Hypertension 1999; 34: Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev 1990; 70: Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? J Hypertens 1986; 4: Izzard AS, Heagerty AM, Leenen FH. The amplifier hypothesis: persisting dissent. J Hypertens 2002; 20: Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci 2002; 17: Schiffrin EL, Deng LY. Relationship between smallartery structure and systolic, diastolic and pulse pressure in essential hypertension. J Hypertens 1999; 17: Rizzoni D, Muiesan ML, Porteri E, Castellano M, Zulli R, Bettoni G et al. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997; 15: Rizzoni D, Palombo C, Porteri E, Muiesan ML, Kozàkovà M, La Canna G et al. Relationships between coronary vasodilator capacity and small artery remodeling in hypertensive patients. J Hypertens 2003; 21: Rizzoni D, Porteri E, Boari GEM, De Ciuceis C, Sleiman I, Muiesan ML et al. Prognostic significance of small artery structure in hypertension. Circulation 2003; 108: De Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GEM et al. Structural alterations of subcutaneous small arteries may predict major cardiovascular events in hypertensive patients. Am J Hypertens 2007; 20: Mathiassen ON, Buus NH, Sihm I, Thybo NK, Morn B, Schroeder AP et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007; 25: Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 2005; 23: Rizzoni D, Porteri E, Platto C, Rizzardi N, De Ciuceis C, Boari GE et al. Morning rise of blood pressure and subcutaneous small resistance artery structure. J Hypertens 2007; 25: Agabiti Rosei E, Rizzoni D. The effects of hypertension on the structure of human resistance arteries. In: Lip GYH, Hall JE (eds). Comprehensive Hypertension. Elsevier: Mosby, 2007, Chapter 47, pp Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004; 17(12 Pt. 1): Savoia C, Touyz RM, Endemann DH, Pu Q, Ko EA, De Ciuceis C et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006; 48: Mathiassen ON, Buus NH, Larsen ML, Mulvany MJ, Christensen KL. Small artery structure adapts to vasodilatation rather than to blood pressure during antihypertensive treatment. J Hypertens 2007; 25: Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008; 51: Ting CT, Yang TM, Chen JW, Chang MS, Yin FC. Arterial hemodynamics in human hypertension. Effects of angiotensin converting enzyme inhibition. Hypertension 1993; 22: Chen CH, Ting CT, Lin SJ, Hsu FCP, Siu CO, Chou P et al. Different effects of fosinopril and atenolol on wave reflections in hypertension. Hypertension 1995; 25: Ting CT, Chen C-H, Chang M-S, Yin FCP. Short- and long-term effects of antihypertensive drugs on arterial reflections compliance and impedance. Hypertension 1995; 26: Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation 2005; 112: London GM, Asmar RG, O Rourke MF, Safar ME, Reason Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: Hirata K, Vlachopoulos C, Adji A, O Rourke MF. Benefits from angiotensin-converting enzyme inhibitor beyond blood pressure lowering : beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23: Williams B, Lacy PS, Thorm SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: De Luca N, Asmar R, London GM, O Rourke MF, Safar ME, TEASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low- dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22: Dhakam Z, Yasmin, MacEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26:

Blood Pressure Response Under Chronic Antihypertensive Drug Therapy

Blood Pressure Response Under Chronic Antihypertensive Drug Therapy Journal of the American College of Cardiology Vol. 53, No. 5, 29 29 by the American College of Cardiology Foundation ISSN 735-197/9/$36. Published by Elsevier Inc. doi:1.116/j.jacc.28.9.46 Hypertension

More information

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France

Effects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance

More information

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski

Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly. Piotr Jankowski Arterial stiffness and central BP as goals for antihypertensive therapy in pre- and elderly Piotr Jankowski I Department of Cardiology and Hypertension CM UJ, Kraków, Poland piotrjankowski@interia.pl Vienna,

More information

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity Clinical application of Arterial stiffness pulse wave analysis pulse wave velocity Arterial system 1. Large arteries: elastic arteries Aorta, carotid, iliac, Buffering reserve: store blood during systole

More information

Central Pressures and Prehypertension

Central Pressures and Prehypertension Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos

More information

Measurement of Arterial Stiffness: Why should I measure both PWA and PWV?

Measurement of Arterial Stiffness: Why should I measure both PWA and PWV? Measurement of Arterial Stiffness: Why should I measure both PWA and PWV? Central blood pressure and measures of arterial stiffness have been shown to be powerful predictors of major cardiovascular events,

More information

Pulse pressure as a haemodynamic variable in systolic heart failure Petrie, Colin James

Pulse pressure as a haemodynamic variable in systolic heart failure Petrie, Colin James University of Groningen Pulse pressure as a haemodynamic variable in systolic heart failure Petrie, Colin James IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you

More information

Can Arterial Stiffness Be Reversed? And If So, What Are the Benefits?

Can Arterial Stiffness Be Reversed? And If So, What Are the Benefits? ...SYMPOSIUM PROCEEDINGS... Can Arterial Stiffness Be Reversed? And If So, What Are the Benefits? Based on a presentation by Michel E. Safar, MD Presentation Summary Systolic and diastolic blood pressure

More information

...SELECTED ABSTRACTS...

...SELECTED ABSTRACTS... The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.

More information

a Centre d Investigations Préventives et Cliniques, b Hypertension and Received 18 July 2007 Revised 11 February 2008 Accepted 13 February 2008

a Centre d Investigations Préventives et Cliniques, b Hypertension and Received 18 July 2007 Revised 11 February 2008 Accepted 13 February 2008 1072 Original article Cardiovascular risk as defined in the 2003 European blood pressure classification: the assessment of an additional predictive value of pulse pressure on mortality Frédérique Thomas

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

How clinically important are the results of the large trials in hypertension?

How clinically important are the results of the large trials in hypertension? How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université

More information

TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients

TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients CARDIOVASCULAR TECHNOLOGY AND INDICATION SERVICE TODAY S TOPIC Blood Pressure & Pulse Wave Measurement Combined in One Procedure Re-classification of Risk Patients SERIES Hypertension Management in the

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota

More information

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo?

Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Danno d organo bersaglio e rischio CV. Persiste un ruolo prognostico oltre la patologia d organo? Prof. Massimo Salvetti Clinica Medica University of Brescia Percieved risk Actual risk Sehestedt et al,

More information

Arterial Stiffness: pathophysiology and clinical impact. Gérard M. LONDON Manhès Hospital Fleury-Mérogis/Paris, France

Arterial Stiffness: pathophysiology and clinical impact. Gérard M. LONDON Manhès Hospital Fleury-Mérogis/Paris, France Arterial Stiffness: pathophysiology and clinical impact Gérard M. LONDON Manhès Hospital Fleury-Mérogis/Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance Arterial

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive drugs SUMMARY Made by: Lama Shatat Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone

More information

IS PVR THE RIGHT METRIC FOR RV AFTERLOAD?

IS PVR THE RIGHT METRIC FOR RV AFTERLOAD? Echo Doppler Assessment of PVR The Children s Hospital Denver, CO Robin Shandas Professor of Pediatrics, Cardiology Professor of Mechanical Engineering Director, Center for Bioengineering University of

More information

3 Aging, Arterial Stiffness,

3 Aging, Arterial Stiffness, Chapter 3 / Mechanisms of Hypertension 23 3 Aging, Arterial Stiffness, and Systolic Hypertension Joseph L. Izzo, Jr., MD CONTENTS INTRODUCTION POPULATION STUDIES PATHOPHYSIOLOGY NONINVASIVE MEASUREMENT

More information

Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease

Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease ...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호

Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Which method is better to measure arterial stiffness; augmentation index, pulse wave velocity, carotid distensibility? 전북의대내과 김원호 Arterial stiffness Arterial stiffness is inversely related to arterial

More information

Managing hypertension: a question of STRATHE

Managing hypertension: a question of STRATHE (2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,

More information

Should beta blockers remain first-line drugs for hypertension?

Should beta blockers remain first-line drugs for hypertension? 1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,

More information

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz

Special Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =

More information

BIOL 219 Spring Chapters 14&15 Cardiovascular System

BIOL 219 Spring Chapters 14&15 Cardiovascular System 1 BIOL 219 Spring 2013 Chapters 14&15 Cardiovascular System Outline: Components of the CV system Heart anatomy Layers of the heart wall Pericardium Heart chambers, valves, blood vessels, septum Atrioventricular

More information

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France

Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;

More information

The arterial system has a dual function:

The arterial system has a dual function: Hellenic J Cardiol 2010; 51: 385-390 Editorial Aortic Stiffness: Prime Time for Integration into Clinical Practice? Charalambos Vlachopoulos, Nikolaos Alexopoulos, Christodoulos Stefanadis Peripheral Vessels

More information

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016

Director of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016 The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief

More information

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure 801 Original Article Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure Akira YAMASHINA, Hirofumi TOMIYAMA, Tomio ARAI, Yutaka KOJI, Minoru YAMBE, Hiroaki MOTOBE, Zydem

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Arterial Pressure in CKD5 - ESRD Population Gérard M. London

Arterial Pressure in CKD5 - ESRD Population Gérard M. London Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black

More information

Υπέρταση στις γυναίκες

Υπέρταση στις γυναίκες Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe

More information

Clinical usefulness of the second peak of radial systolic blood pressure for estimation of aortic systolic blood pressure

Clinical usefulness of the second peak of radial systolic blood pressure for estimation of aortic systolic blood pressure (2009) 23, 538 545 & 2009 Macmillan Publishers Limited All rights reserved 0950-9240/09 $32.00 www.nature.com/jhh ORIGINAL ARTICLE Clinical usefulness of the second peak of radial systolic blood pressure

More information

ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION

ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION Jung-Sun Kim a and Sungha Park a,b, a Division of Cardiology, b Cardiovascular Genome Center, Yonsei Cardiovascular Center,

More information

6 In the CAFE study, the main difference in central aortic pressures resulted from an increase in AIx ⴝ augmentation index pressure wave reflections (

6 In the CAFE study, the main difference in central aortic pressures resulted from an increase in AIx ⴝ augmentation index pressure wave reflections ( Journal of the American College of Cardiology 9 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 54, No. 8, 9 ISSN 735-197/9/$36. doi:116/j.jacc.9.2.88 CME Impact of Heart

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Therefore MAP=CO x TPR = HR x SV x TPR

Therefore MAP=CO x TPR = HR x SV x TPR Regulation of MAP Flow = pressure gradient resistance CO = MAP TPR Therefore MAP=CO x TPR = HR x SV x TPR TPR is the total peripheral resistance: this is the combined resistance of all blood vessels (remember

More information

What is the mechanism of the audible carotid bruit? How does one calculate the velocity of blood flow?

What is the mechanism of the audible carotid bruit? How does one calculate the velocity of blood flow? CASE 8 A 65-year-old man with a history of hypertension and coronary artery disease presents to the emergency center with complaints of left-sided facial numbness and weakness. His blood pressure is normal,

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results

Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais

More information

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs (2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal

More information

Coronary artery disease (CAD) risk factors

Coronary artery disease (CAD) risk factors Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes

More information

Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις

Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Η σημασία της αρτηριακής σκληρίας στην εκτίμηση της διαστολικής δυσλειτουργίας στην υπέρταση. Θεραπευτικές παρεμβάσεις Ελένη Τριανταφυλλίδη Επιμελήτρια Α Β Πανεπιστημιακή Καρδιολογική Κλινική Αττικό Νοσοκομείο

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension

High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension (2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers

More information

Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness

Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness (2004) 18, 469 473 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effects of coexisting hypertension and type II diabetes mellitus on arterial

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide

Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical

More information

Impedance Cardiography (ICG) Application of ICG for Hypertension Management

Impedance Cardiography (ICG) Application of ICG for Hypertension Management Application of ICG for Hypertension Management 1mA @ 100 khz Impedance Cardiography (ICG) Non-invasive Beat-to-beat Hemodynamic Monitoring Diastole Systole Aortic valve is closed No blood flow in the aorta

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Special Lecture 10/28/2012

Special Lecture 10/28/2012 Special Lecture 10/28/2012 HYPERTENSION Dr. HN Mayrovitz Special Lecture 10/28/2012 Arterial Blood Pressure (ABP) - Definitions ABP Review Indirect Oscillographic Method Resistance (R), Compliance (C)

More information

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle

More information

Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients

Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients Journal of Human Hypertension (2017), 1 6 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-9240/17 www.nature.com/jhh REVIEW Role of nebivolol in the control and management

More information

FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION

FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

Clinical Trials. Pierre Boutouyrie, Assya Achouba, Patrick Trunet, Stéphane Laurent, for the EXPLOR Trialist Group

Clinical Trials. Pierre Boutouyrie, Assya Achouba, Patrick Trunet, Stéphane Laurent, for the EXPLOR Trialist Group Clinical Trials Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study Pierre Boutouyrie, Assya Achouba, Patrick

More information

CVS Hemodynamics. Faisal I. Mohammed, MD,PhD.

CVS Hemodynamics. Faisal I. Mohammed, MD,PhD. CVS Hemodynamics Faisal I. Mohammed, MD,PhD. Objectives point out the physical characteristics of the circulation: distribution of blood volume total cross sectional area velocity blood pressure List the

More information

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure

Estimated Pulse Wave Velocity Calculated from Age and Mean Arterial Blood Pressure Received: August 19, 2016 Accepted after revision: November 4, 2016 Published online: December 1, 2016 2235 8676/16/0044 0175$39.50/0 Mini-Review Estimated Pulse Wave Velocity Calculated from Age and Mean

More information

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF

Hypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step

More information

Blood Flow, Blood Pressure, Cardiac Output. Blood Vessels

Blood Flow, Blood Pressure, Cardiac Output. Blood Vessels Blood Flow, Blood Pressure, Cardiac Output Blood Vessels Blood Vessels Made of smooth muscle, elastic and fibrous connective tissue Cells are not electrically coupled Blood Vessels Arteries arterioles

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Department of Intensive Care Medicine UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS

Department of Intensive Care Medicine UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS Department of Intensive Care Medicine UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS UNDERSTANDING CIRCULATORY FAILURE IN SEPSIS a mismatch between tissue perfusion and metabolic demands the heart, the vasculature

More information

Atherosclerosis, Large Arteries and Cardiovascular Risk

Atherosclerosis, Large Arteries and Cardiovascular Risk U U U U U U U U U U U U U U U U U U U U U U U U U U U Atherosclerosis, Large Arteries and Cardiovascular Risk U U U U U U U U U U U U U U U U U U U U U U U U U U U Advances in Cardiology Vol. 44 Series

More information

Differences in Effects of Age and Blood Pressure on Augmentation Index

Differences in Effects of Age and Blood Pressure on Augmentation Index Original Article Differences in Effects of Age and Blood Pressure on Augmentation Index Hirofumi Tomiyama, 1 Mari Odaira, 1 Kazutaka Kimura, 1 Chisa Matsumoto, 1 Kazuki Shiina, 1 Kazuo Eguchi, 2 Hiroshi

More information

Hypertension Compendium

Hypertension Compendium Hypertension Compendium Circulation Research Compendium on Hypertension The Epidemiology of Blood Pressure and Its Worldwide Management Genetic and Molecular Aspects of Hypertension Hypertension: Renin

More information

The monthly ESH guide through publications

The monthly ESH guide through publications NEWSLETTER APRIL 2016 The monthly ESH guide through publications Edited by: Prof Costas Tsioufis, ESH Secretary and Dr Alex Kasiakogias Effects of hypertension treatment on heart failure: insights from

More information

The Conduit Artery Functional Endpoint (CAFE) study in ASCOT

The Conduit Artery Functional Endpoint (CAFE) study in ASCOT (2001) 15, Suppl 1, S69 S73 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh A Sub-study of the ASCOT Trial The Conduit Artery Functional Endpoint (CAFE) study in

More information

Pulse Pressure Amplification

Pulse Pressure Amplification Journal of the American College of Cardiology Vol. 55, No. 10, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.061

More information

Systolic Hypertension in the Elderly: Addressing an Unmet Need

Systolic Hypertension in the Elderly: Addressing an Unmet Need REVIEW Systolic Hypertension in the Elderly: Addressing an Unmet Need Daniel A. Duprez, MD, PhD Cardiovascular Division, Medical School, University of Minnesota, Minn. ABSTRACT Systolic hypertension is

More information

Blood pressure control. Rok Humar, PhD Department of Research

Blood pressure control. Rok Humar, PhD Department of Research Blood pressure control Rok Humar, PhD Department of Research Mean arterial blood pressure is determined by Blood volume Cardiac output Peripheral resistance Blood capacitance Resistance of the system to

More information

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia?

Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? 2012. 4. 20-21 춘계심장학회 _ 부산 Can Anti-hypertension Therapy Reverse Vascular Aging and Dementia? Jeong Bae Park, MD, PhD Cardiology, Cheil General Hospital, Kwandong University, Seoul, Korea The Pulse : revived

More information

OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich,

OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, The effect of renal denervation in patients with advanced heart failure: OLOMOUC I Study M. Táborský, M. Lazárová, J. Václavík, D. Richter ESC 2012, Munich, 27.08.2012 Disclosures MT: honoraria Bayer,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:

More information

DIASTOLIC HEART FAILURE

DIASTOLIC HEART FAILURE DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction

More information

Measurement and Analysis of Radial Artery Blood Velocity in Young Normotensive Subjects

Measurement and Analysis of Radial Artery Blood Velocity in Young Normotensive Subjects Informatica Medica Slovenica 2003; 8(1) 15 Research Paper Measurement and Analysis of Radial Artery Blood in Young Normotensive Subjects Damjan Oseli, Iztok Lebar Bajec, Matjaž Klemenc, Nikolaj Zimic Abstract.

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine

More information

Hypertension, Systolic Blood Pressure, and Large Arteries

Hypertension, Systolic Blood Pressure, and Large Arteries Hypertension, Systolic Blood Pressure, and Large Arteries Michel E. Safar, MD KEYWORDS Hypertension Pulse pressure Larges arteries Arterial stiffness Wave reflections The authors of epidemiologic studies

More information

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Pathophysiology of Vascular Function in CKD. INSERM U970 Hôpital Européen Georges Pompidou Paris

Pathophysiology of Vascular Function in CKD. INSERM U970 Hôpital Européen Georges Pompidou Paris Pathophysiology of Vascular Function in CKD Gérard M. London INSERM U970 Hôpital Européen Georges Pompidou Paris Arterial Pathophysiology and Cardiovascular Diseases in CKD Systolic BP; Diastolic BP Arteriosclerosis

More information

When should you treat blood pressure in the young?

When should you treat blood pressure in the young? ESC Stockholm - Dilemmas in Cardiovascular Disease Prevention in the Young: 30 th August 2010 When should you treat blood pressure in the young? Bryan Williams MD FRCP FAHA FESC Professor of Medicine Department

More information

Special circulations, Coronary, Pulmonary. Faisal I. Mohammed, MD,PhD

Special circulations, Coronary, Pulmonary. Faisal I. Mohammed, MD,PhD Special circulations, Coronary, Pulmonary Faisal I. Mohammed, MD,PhD 1 Objectives Describe the control of blood flow to different circulations (Skeletal muscles, pulmonary and coronary) Point out special

More information

Brachial artery hyperaemic blood flow velocity and left ventricular geometry

Brachial artery hyperaemic blood flow velocity and left ventricular geometry (2011), 1 5 & 2011 Macmillan Publishers Limited All rights reserved 0950-9240/11 www.nature.com/jhh ORIGINAL ARTICLE Brachial artery hyperaemic blood flow velocity and left ventricular geometry SJ Järhult,

More information

The Cardiac Cycle Clive M. Baumgarten, Ph.D.

The Cardiac Cycle Clive M. Baumgarten, Ph.D. The Cardiac Cycle Clive M. Baumgarten, Ph.D. OBJECTIVES: 1. Describe periods comprising cardiac cycle and events within each period 2. Describe the temporal relationships between pressure, blood flow,

More information

BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1

BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1 BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1 Terms you should understand: hemorrhage, intrinsic and extrinsic mechanisms, anoxia, myocardial contractility, residual

More information

The right heart: the Cinderella of heart failure

The right heart: the Cinderella of heart failure The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland

State of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle  holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/28524 holds various files of this Leiden University dissertation Author: Djaberi, Roxana Title: Cardiovascular risk assessment in diabetes Issue Date: 2014-09-04

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Research Article The Age-Dependent Contribution of Aortic Incident and Reflected Pressure Waves to Central Blood Pressure in African-Americans

Research Article The Age-Dependent Contribution of Aortic Incident and Reflected Pressure Waves to Central Blood Pressure in African-Americans SAGE-Hindawi Access to Research International Hypertension Volume 211, Article ID 58573, 6 pages doi:1.461/211/58573 Research Article The Age-Dependent Contribution of Aortic Incident and Reflected Pressure

More information